Does MEPOLIZUMAB Cause Hyperleukocytosis? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Hyperleukocytosis have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.0% of all adverse event reports for MEPOLIZUMAB.
14
Reports of Hyperleukocytosis with MEPOLIZUMAB
0.0%
of all MEPOLIZUMAB reports
0
Deaths
14
Hospitalizations
How Dangerous Is Hyperleukocytosis From MEPOLIZUMAB?
Of the 14 reports, 14 (100.0%) required hospitalization.
Is Hyperleukocytosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does MEPOLIZUMAB Cause?
Asthma (11,033)
Dyspnoea (9,192)
Wheezing (6,093)
Product dose omission issue (5,873)
Cough (4,577)
Pneumonia (4,107)
Therapeutic product effect incomplete (4,106)
Drug ineffective (3,880)
Loss of personal independence in daily activities (3,566)
Fatigue (2,656)
What Other Drugs Cause Hyperleukocytosis?
CYCLOPHOSPHAMIDE (55)
PREDNISONE (54)
TRETINOIN (52)
ARSENIC TRIOXIDE (49)
RITUXIMAB (49)
ACETAMINOPHEN (44)
VINCRISTINE (44)
DEXAMETHASONE (42)
PANTOPRAZOLE (38)
AMOXICILLIN (36)
Which MEPOLIZUMAB Alternatives Have Lower Hyperleukocytosis Risk?
MEPOLIZUMAB vs MEPROBAMATE
MEPOLIZUMAB vs MERCAPTOPURINE
MEPOLIZUMAB vs MEROPENEM
MEPOLIZUMAB vs MEROPENEM ANHYDROUS
MEPOLIZUMAB vs MESALAMINE